Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091715
Status:
COMPLETED
Last Update Posted:
2011-08-30
First Post:
2004-09-16
Brief Title:
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multicenter Study to Assess the Efficacy Safety and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension PAH
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present trial investigates a possible use of oral bosentan which is currently approved for the treatment of symptoms of pulmonary arterial hypertension PAH Class III and IV to patients suffering from PAH Class II
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AC-052-364 | None | None | None |